Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Double-blind, Comparative, Randomized Tolerability, Safety and Immunogenicity Trial of Flu-M [Inactivated Split Influenza Vaccine], vs. the Ultrix® Vaccine in Children Aged 6 to 17 Years (Inclusive)

NCT05317767 is registered in ClinicalTrials.gov with St. Petersburg Research Institute of Vaccines and Sera as lead sponsor.

NCT NCT05317767
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05317767 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Double-blind, Comparative, Randomized Tolerability, Safety and Immunogenicity Trial of Flu-M [Inactivated Split Influenza Vaccine], vs. the Ultrix® Vaccine in Children Aged 6 to 17 Years (Inclusive)
Lead sponsor
St. Petersburg Research Institute of Vaccines and Sera
Phase
Phase 3
Overall status
Completed
Start date
February 10, 2020
Completion date
September 14, 2020
Enrollment
600 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

influenza